Ivan Bieche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3559177/publications.pdf

Version: 2024-02-01

20961 10389 19,164 369 72 115 citations h-index g-index papers 376 376 376 31187 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 1324-1334.	10.7	897
2	Characterization of a Germ-Line Deletion, Including the Entire <i>INK4/ARF</i> Locus, in a Melanoma-Neural System Tumor Family: Identification of <i>ANRIL</i> , an Antisense Noncoding RNA Whose Expression Coclusters with <i>ARF</i> . Cancer Research, 2007, 67, 3963-3969.	0.9	582
3	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer Clinical Cancer Research, 2006, 12, 1157-1167.	7.0	495
4	<i>ANRIL</i> , a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB Journal, 2011, 25, 444-448.	0.5	413
5	Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenetics and Genomics, 2007, 17, 731-742.	1.5	300
6	Genetic alterations in breast cancer. Genes Chromosomes and Cancer, 1995, 14, 227-251.	2.8	251
7	Circulating tumor DNA as a nonâ€invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Molecular Oncology, 2015, 9, 783-790.	4.6	248
8	SWI/SNF Chromatin Remodeling and Human Malignancies. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 145-171.	22.4	242
9	Molecular Profiling of Inflammatory Breast Cancer. Clinical Cancer Research, 2004, 10, 6789-6795.	7.0	213
10	Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocrine-Related Cancer, 2006, 13, 1109-1120.	3.1	208
11	NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Human Mutation, 2010, 31, E1506-E1518.	2.5	208
12	Inhibitory signalling to the Arp2/3 complex steers cell migration. Nature, 2013, 503, 281-284.	27.8	208
13	Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology, 2004, 126, 1323-1329.	1.3	205
14	Prognostic value of ERBB family mRNA expression in breast carcinomas. International Journal of Cancer, 2003, 106, 758-765.	5.1	184
15	Ex Vivo Priming of Endothelial Progenitor Cells With SDF-1 Before Transplantation Could Increase Their Proangiogenic Potential. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 644-650.	2.4	174
16	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Journal of Hepatology, 2012, 56, 527-532.	3.7	165
17	CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain, 2015, 138, 2383-2398.	7.6	163
18	Liver Gene Expression Signature of Mild Fibrosis in Patients With Chronic Hepatitis C. Gastroenterology, 2005, 129, 2064-2075.	1.3	161

#	Article	IF	Citations
19	NF-kappa B genes have a major role in Inflammatory Breast Cancer. BMC Cancer, 2008, 8, 41.	2.6	155
20	microRNA expression profile in a large series of bladder tumors: Identification of a 3â€miRNA signature associated with aggressiveness of muscleâ€invasive bladder cancer. International Journal of Cancer, 2013, 132, 2479-2491.	5.1	152
21	PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Research, 2012, 14, R28.	5.0	151
22	Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function. Drug Metabolism and Disposition, 2009, 37, 1528-1538.	3.3	148
23	Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology, 2005, 332, 130-144.	2.4	145
24	CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocrine-Related Cancer, 2007, 14, 1039-1052.	3.1	145
25	Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Molecular Cancer, 2008, 7, 41.	19.2	145
26	TaqMan PCR-based Gene Dosage Assay for Predictive Testing in Individuals from a Cancer Family with INK4 Locus Haploinsufficiency. Clinical Chemistry, 1999, 45, 982-986.	3.2	141
27	Genome-Wide DNA Methylation Profiling of CpG Islands in Breast Cancer Identifies Novel Genes Associated with Tumorigenicity. Cancer Research, 2011, 71, 2988-2999.	0.9	141
28	Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver International, 2010, 30, 1259-1269.	3.9	139
29	A Six-Gene Signature Predicting Breast Cancer Lung Metastasis. Cancer Research, 2008, 68, 6092-6099.	0.9	131
30	Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy, 2014, 10, 2122-2142.	9.1	130
31	Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood, 2010, 116, 4523-4531.	1.4	126
32	Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets. BioMed Research International, 2015, 2015, 1-14.	1.9	122
33	Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene, 2004, 23, 2408-2419.	5.9	119
34	PAR-1 Activation on Human Late Endothelial Progenitor Cells Enhances Angiogenesis In Vitro With Upregulation of the SDF-1/CXCR4 System. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2321-2327.	2.4	119
35	Quantification of estrogen receptor $\hat{l}\pm$ and \hat{l}^2 expression in sporadic breast cancer. Oncogene, 2001, 20, 8109-8115.	5.9	118
36	DNA methylation imprinting marks and DNA methyltransferase expression in human spermatogenic cell stages. Epigenetics, 2011, 6, 1354-1361.	2.7	118

#	Article	IF	CITATIONS
37	Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data. Cancer Research, 2015, 75, 1560-1566.	0.9	117
38	Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nature Communications, 2014, 5, 5005.	12.8	114
39	Thrombospondin-1 Is a Plasmatic Marker of Peripheral Arterial Disease That Modulates Endothelial Progenitor Cell Angiogenic Properties. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 551-559.	2.4	111
40	Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. International Journal of Cancer, 2010, 126, 545-562.	5.1	110
41	<i>In vivo</i> hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. Journal of Pathology, 2010, 221, 264-274.	4.5	109
42	RASSF4/AD037 Is a Potential Ras Effector/Tumor Suppressor of the RASSF Family. Cancer Research, 2004, 64, 8688-8693.	0.9	108
43	ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial–Mesenchymal Transition and Invasion. Cancer Research, 2012, 72, 3593-3606.	0.9	107
44	Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1. Journal of the National Cancer Institute, 2011, 103, 1713-1722.	6.3	106
45	A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Gastroenterology, 2003, 124, 651-659.	1.3	101
46	Bone Morphogenetic Proteins 2 and 4 Are Selectively Expressed by Late Outgrowth Endothelial Progenitor Cells and Promote Neoangiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2137-2143.	2.4	101
47	An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood, 2003, 101, 1833-1840.	1.4	99
48	OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. European Journal of Cancer, 2014, 50, 2463-2477.	2.8	98
49	Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemotherapy and Pharmacology, 2008, 62, 305-313.	2.3	97
50	PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer, 2013, 13, 545.	2.6	96
51	Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Human Molecular Genetics, 2015, 24, 5965-5976.	2.9	96
52	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2736-2741.	7.1	95
53	Tumor <i>PIK3CA</i> Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. Journal of Clinical Oncology, 2018, 36, 981-990.	1.6	95
54	Molecular Profiling of Hepatocellular Carcinomas (HCC) Using a Large-Scale Real-Time RT-PCR Approach. American Journal of Pathology, 2003, 163, 733-741.	3.8	90

#	Article	IF	CITATIONS
55	Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Research, 2004, 6, R252-63.	5.0	89
56	Candidate Genes on Chromosome 9q33-34 Involved in the Progression of Childhood Ependymomas. Journal of Clinical Oncology, 2009, 27, 1884-1892.	1.6	89
57	Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Critical Care Medicine, 2006, 34, 219-222.	0.9	88
58	CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer, 2010, 10, 66.	2.6	87
59	Placenta-Specific INSL4 Expression Is Mediated by a Human Endogenous Retrovirus Element1. Biology of Reproduction, 2003, 68, 1422-1429.	2.7	86
60	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Science Translational Medicine, 2020, 12, .	12.4	86
61	Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Molecular Cancer, 2004, 3, 20.	19.2	85
62	Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances ⟨i⟩in vitro⟨/i⟩ angiogenesis with upâ€regulation of integrin α⟨sub⟩6⟨/sub⟩. Journal of Cellular and Molecular Medicine, 2007, 11, 1149-1161.	3.6	85
63	Expression of <i>ANRIL</i> â€"Polycomb Complexesâ€" <i>CDKN2A/B/ARF</i> Genes in Breast Tumors: Identification of a Two-Gene (<i>EZH2/CBX7</i>) Signature with Independent Prognostic Value. Molecular Cancer Research, 2016, 14, 623-633.	3.4	84
64	Identification of 5 novel genes methylated in breast and other epithelial cancers. Molecular Cancer, 2010, 9, 51.	19.2	83
65	Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene, 2006, 380, 127-136.	2.2	82
66	Tubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon. EMBO Journal, 2014, 33, 2247-2260.	7.8	82
67	Role of <i>WISP-2/CCN5</i> in the Maintenance of a Differentiated and Noninvasive Phenotype in Human Breast Cancer Cells. Molecular and Cellular Biology, 2008, 28, 1114-1123.	2.3	80
68	Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene, 2002, 21, 7593-7597.	5.9	78
69	PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Nature Communications, 2020, 11, 4053.	12.8	77
70	Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis and Rheumatism, 2005, 52, 2917-2925.	6.7	76
71	Control of MT1-MMP transport by atypical PKC during breast-cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1872-9.	7.1	76
72	p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. Oncogene, 2016, 35, 344-357.	5.9	76

#	Article	IF	Citations
73	Gene Expression Profiling of the Hedgehog Signaling Pathway in Human Meningiomas. Molecular Medicine, 2010, 16, 262-270.	4.4	7 5
74	The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. Clinical Epigenetics, 2015, 7, 57.	4.1	75
75	Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. British Journal of Cancer, 2016, 114, 1395-1404.	6.4	7 5
76	Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Human Molecular Genetics, 2005, 14, 1293-1303.	2.9	74
77	Correction of Brain Oligodendrocytes by AAVrh.10 Intracerebral Gene Therapy in Metachromatic Leukodystrophy Mice. Human Gene Therapy, 2012, 23, 903-914.	2.7	73
78	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. Journal of the National Cancer Institute, 2016, 108, djv362.	6.3	71
79	Aspergillus fumigatus germ tube growth and not conidia ingestion induces expression of inflammatory mediator genes in the human lung epithelial cell line A549. Journal of Medical Microbiology, 2009, 58, 174-179.	1.8	70
80	Role of the Focal Adhesion Protein Kindlin-1 in Breast Cancer Growth and Lung Metastasis. Journal of the National Cancer Institute, 2011, 103, 1323-1337.	6.3	69
81	High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. PLoS ONE, 2018, 13, e0190619.	2.5	69
82	Genetic pathways in the evolution of breast ductal carcinomain situ. Journal of Pathology, 2002, 196, 280-286.	4.5	68
83	Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. Human Gene Therapy Clinical Development, 2015, 26, 113-124.	3.1	68
84	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. Clinical Cancer Research, 2018, 24, 5767-5771.	7.0	68
85	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Oncolmmunology, 2019, 8, e1581556.	4.6	68
86	Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Human Molecular Genetics, 2010, 19, 147-158.	2.9	67
87	Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 1709-1719.	4.1	67
88	miRNA expression profiling of inflammatory breast cancer identifies a 5â€miRNA signature predictive of breast tumor aggressiveness. International Journal of Cancer, 2013, 133, 1614-1623.	5.1	67
89	Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. British Journal of Cancer, 2016, 114, 177-187.	6.4	67
90	Tubulin glycylation controls primary cilia length. Journal of Cell Biology, 2017, 216, 2701-2713.	5.2	67

#	Article	IF	CITATIONS
91	mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and geneâ€expression levels. Cancer Science, 2008, 99, 1992-2003.	3.9	66
92	Update on inflammatory breast cancer. Breast Cancer Research, 2005, 7, 52-8.	5.0	65
93	Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. Journal of Molecular Endocrinology, 2009, 42, 87-103.	2.5	65
94	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. Clinical Cancer Research, 2019, 25, 2109-2115.	7.0	65
95	Cortical branched actin determines cell cycle progression. Cell Research, 2019, 29, 432-445.	12.0	64
96	In vivo altered unfolded protein response and apoptosis in livers from lipopolysaccharide-challenged cirrhotic rats. Journal of Hepatology, 2007, 46, 1075-1088.	3.7	62
97	The cytosolic carboxypeptidases CCP2 and CCP3 catalyze posttranslational removal of acidic amino acids. Molecular Biology of the Cell, 2014, 25, 3017-3027.	2.1	62
98	Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients. Clinical Cancer Research, 2012, 18, 2838-2849.	7.0	61
99	Analyses of MYC, ERBB2, and CCND1 Genes in Benign and Malignant Thyroid Follicular Cell Tumors by Real-Time Polymerase Chain Reaction. Thyroid, 2001, 11, 147-152.	4.5	60
100	The Wnt Antagonist Dickkopf-1 Increases Endothelial Progenitor Cell Angiogenic Potential. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2544-2552.	2.4	60
101	Quantitative PCR high-resolution melting (qPCR-HRM) curve analysis, a new approach to simultaneously screen point mutations and large rearrangements: application to <i>MLH1</i> germline mutations in Lynch syndrome. Human Mutation, 2009, 30, 867-875.	2.5	58
102	Changes in Autophagic Response in Patients with Chronic Hepatitis C Virus Infection. American Journal of Pathology, 2011, 178, 2708-2715.	3.8	58
103	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Modern Pathology, 2018, 31, 68-82.	5. 5	58
104	Cell death and neuronal differentiation of glioblastoma stemâ€ike cells induced by neurogenic transcription factors. Glia, 2013, 61, 225-239.	4.9	57
105	Alterations in the balance of tubulin glycylation and glutamylation in photoreceptors leads to retinal degeneration. Journal of Cell Science, 2017, 130, 938-949.	2.0	57
106	Clinical Relevance of Tumor Cells with Stem-Like Properties in Pediatric Brain Tumors. PLoS ONE, 2011, 6, e16375.	2.5	57
107	Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26365.	1.5	56
108	ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis. Breast Cancer Research, 2018, 20, 73.	5.0	56

#	Article	IF	CITATIONS
109	Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway. PLoS ONE, 2010, 5, e15647.	2.5	56
110	IL- $1\hat{l}^2$ produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. Oncotarget, 2015, 6, 29034-29047.	1.8	56
111	Genetics, Genomics, and Proteomics: Implications for the Diagnosis and the Treatment of Chronic Hepatitis C. Seminars in Liver Disease, 2007, 27, 013-027.	3.6	55
112	Role of estrogen receptor \hat{l}_{\pm} transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas, 2006, 54, 342-351.	2.4	54
113	High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors. Endocrine-Related Cancer, 2007, 14, 691-702.	3.1	54
114	A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Research, 2008, 10, R88.	5.0	54
115	Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy. Molecular Cancer, 2011, 10, 23.	19.2	54
116	Aryl hydrocarbon receptor–dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets. Blood, 2016, 127, 2231-2240.	1.4	54
117	Overexpression of Vascular Endothelial Growth Factor 189 in Breast Cancer Cells Leads to Delayed Tumor Uptake with Dilated Intratumoral Vessels. American Journal of Pathology, 2008, 172, 167-178.	3.8	53
118	Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Breast Cancer Research, 2018, 20, 88.	5.0	53
119	Cross-validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in) Tj ETQq1 1	0.7 81 314	rg B ₹ Overlo
120	1006-1015. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer, 2013, 13, 351.	2.6	52
121	Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP. Genomics, 2003, 81, 400-410.	2.9	51
122	Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52. Clinical Cancer Research, 2008, 14, 5050-5060.	7.0	50
123	Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. Journal of Hepatology, 2011, 54, 1073-1078.	3.7	50
124	Hedgehog pathway activation in human transitional cell carcinoma of the bladder. British Journal of Cancer, 2012, 106, 1177-1186.	6.4	50
125	Deletion mapping of chromosomal region 1p32-pter in primary breast cancer., 1999, 24, 255-263.		49
126	Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis, 2003, 25, 405-411.	2.8	49

#	Article	IF	CITATIONS
127	Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells. Cancer Research, 2009, 69, 4260-4269.	0.9	49
128	Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1. Clinical Cancer Research, 2007, 13, 398-407.	7.0	48
129	Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts. Clinical Cancer Research, 2014, 20, 4314-4325.	7.0	48
130	MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?. BMC Cancer, 2015, 15, 499.	2.6	48
131	$\langle i \rangle$ PIK3CA $\langle i \rangle$ Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy $\hat{A}\pm$ Cetuximab in Cervical Cancer Patients. Clinical Cancer Research, 2015, 21, 2530-2537.	7.0	48
132	Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells. Journal of Cellular and Molecular Medicine, 2008, 12, 975-986.	3.6	47
133	The iron chelator deferasirox synergises with chemotherapy to treat tripleâ€negative breast cancers. Journal of Pathology, 2018, 246, 103-114.	4.5	47
134	Exploring the Distinctive Biological Characteristics of Pilocytic and Low-Grade Diffuse Astrocytomas Using Microarray Gene Expression Profiles. Journal of Neuropathology and Experimental Neurology, 2006, 65, 794-807.	1.7	46
135	Identification of Genes Potentially Involved in the Increased Risk of Malignancy in NF1-Microdeleted Patients. Molecular Medicine, 2011, 17, 79-87.	4.4	46
136	MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics, 2013, 14, 473.	2.8	46
137	A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. British Journal of Cancer, 2013, 108, 1720-1731.	6.4	46
138	Large-scale Real-time Reverse Transcription-PCR Approach of Angiogenic Pathways in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major Independent Prognostic Marker. European Urology, 2009, 56, 678-689.	1.9	45
139	ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels. British Journal of Cancer, 2015, 112, 1059-1066.	6.4	45
140	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. Clinical Cancer Research, 2018, 24, 2605-2615.	7.0	45
141	Immune gene expression in head and neck squamous cell carcinoma patients. European Journal of Cancer, 2019, 121, 210-223.	2.8	45
142	The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis. Clinical Cancer Research, 2014, 20, 358-371.	7.0	44
143	Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site. British Journal of Cancer, 2021, 124, 777-785.	6.4	44
144	Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. British Journal of Cancer, 2016, 114, 1387-1394.	6.4	43

#	Article	IF	Citations
145	MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. Nature Communications, 2015, 6, 8583.	12.8	42
146	The critical role of the <scp>ZNF217</scp> oncogene in promoting breast cancer metastasis to the bone. Journal of Pathology, 2017, 242, 73-89.	4.5	42
147	Baseline \hat{l}^2 -catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. European Journal of Cancer, 2017, 78, 70-81.	2.8	42
148	A single droplet digital PCR for ESR1 activating mutations detection in plasma. Oncogene, 2020, 39, 2987-2995.	5.9	42
149	MUC1 Mucin Gene, Transcripts, and Protein in Adenomas and Papillary Carcinomas of the Thyroid. Thyroid, 1997, 7, 725-731.	4.5	41
150	MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Scientific Reports, 2016, 6, 34935.	3.3	41
151	Loss of heterozygosity of the L-myc oncogene in human breast tumors. Human Genetics, 1990, 85, 101-5.	3.8	40
152	Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts. Molecular Cancer Therapeutics, 2012, 11, 2693-2703.	4.1	39
153	Tubulin polyglutamylation is a general traffic control mechanism in hippocampal neurons. Journal of Cell Science, 2020, 133, .	2.0	39
154	Gene Expression Profiling of ERBB Receptors and Ligands in Human Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2006, 175, 1127-1132.	0.4	38
155	11q13 Amplification in local recurrence of human primary breast cancer. Genes Chromosomes and Cancer, 1995, 12, 128-133.	2.8	37
156	Similar NF-κB Gene Signatures in TNF-α Treated Human Endothelial Cells and Breast Tumor Biopsies. PLoS ONE, 2011, 6, e21589.	2.5	37
157	Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound. Marine Drugs, 2013, 11, 944-959.	4. 6	37
158	Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie. ESMO Open, 2018, 3, e000339.	4.5	37
159	A large collection of integrated genomically characterized patientâ€derived xenografts highlighting the heterogeneity of tripleâ€negative breast cancer. International Journal of Cancer, 2019, 145, 1902-1912.	5.1	37
160	Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia, 2006, 8, 312-318.	5.3	36
161	Differential Distribution of erbB Receptors in Human Clioblastoma Multiforme: Expression of erbB3 in CD133-Positive Putative Cancer Stem Cells. Journal of Neuropathology and Experimental Neurology, 2010, 69, 606-622.	1.7	36
162	Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function. Oncogene, 2018, 37, 6425-6441.	5.9	36

#	Article	IF	CITATIONS
163	Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer. Clinical Cancer Research, 2021, 27, 5869-5877.	7.0	36
164	Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. Breast Cancer Research, 2018, 20, 28.	5.0	35
165	ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. Bioinformatics, 2020, 36, 3888-3889.	4.1	35
166	Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study. Genes Chromosomes and Cancer, 1999, 25, 212-221.	2.8	34
167	The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. Thrombosis and Haemostasis, 2004, 91, 248-254.	3.4	34
168	Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. Clinical Cancer Research, 2004, 10, 3763-3771.	7.0	34
169	Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase CÎ ² Inhibitor Enzastaurin in Colon Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 1308-1317.	4.1	34
170	Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. JNCI Cancer Spectrum, 2019, 3, pkz055.	2.9	34
171	<i>ERBB2</i> mutations associated with solid variant of high-grade invasive lobular breast carcinomas. Oncotarget, 2016, 7, 73337-73346.	1.8	34
172	Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics, 2020, 10, 1531-1543.	10.0	34
173	A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. Cancer Genetics and Cytogenetics, 1997, 98, 75-80.	1.0	33
174	High rate of <i><scp>PIK</scp>3<scp>CA</scp></i> mutations but no <i><scp>TP</scp>53</i> mutations in lowâ€grade adenosquamous carcinoma of the breast. Histopathology, 2018, 73, 273-283.	2.9	33
175	Quantitative RT-PCR in cirrhotic nodules reveals gene expression changes associated with liver carcinogenesis. Journal of Pathology, 2003, 201, 260-267.	4.5	32
176	A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers. Molecular Oncology, 2014, 8, 1441-1457.	4.6	32
177	Unraveling the Role of Huntingtin in Breast Cancer Metastasis. Journal of the National Cancer Institute, 2015, 107, djv208.	6.3	32
178	Vandetanib as a potential new treatment for estrogen receptorâ€negative breast cancers. International Journal of Cancer, 2016, 138, 2510-2521.	5.1	32
179	Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. Oncotarget, 2016, 7, 48206-48219.	1.8	32
180	Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer. Human Pathology, 1999, 30, 809-815.	2.0	31

#	Article	IF	CITATIONS
181	Altered expression pattern of alternatively spliced estrogen receptor \hat{l}^2 transcripts in breast carcinoma. Cancer Letters, 2004, 215, 101-112.	7.2	31
182	Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH. Journal of Molecular Diagnostics, 2009, 11, 524-529.	2.8	31
183	TPD52 represents a survival factor in <i>ERBB2</i> â€amplified breast cancer cells. Molecular Carcinogenesis, 2014, 53, 807-819.	2.7	31
184	A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non–Small Cell Lung Cancer Setting—IFCT/ERMETIC2 Project Part 1. Journal of Molecular Diagnostics, 2014, 16, 45-55.	2.8	31
185	Clinical value of R-spondins in triple-negative and metaplastic breast cancers. British Journal of Cancer, 2017, 116, 1595-1603.	6.4	31
186	Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients. Scientific Reports, 2021, 11, 7870.	3.3	31
187	Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Oncotarget, 2016, 7, 38467-38486.	1.8	31
188	Evaluation of mRNA expression of estrogen receptor \hat{l}^2 and its isoforms in human normal and neoplastic endometrium. International Journal of Cancer, 2004, 110, 783-787.	5.1	30
189	Identification of a three-gene expression signature of poor-prognosis breast carcinoma. Molecular Cancer, 2004, 3, 37.	19.2	30
190	Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient. European Journal of Human Genetics, 2008, 16, 1459-1466.	2.8	30
191	ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor \hat{A} expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocrine-Related Cancer, 2008, 15, 125-138.	3.1	30
192	DNA Repair Gene Expression and Risk of Locoregional Relapse in Breast Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2010, 78, 328-336.	0.8	30
193	Increased secretion of Gas6 by smooth muscle cells in human atherosclerotic carotid plaques. Thrombosis and Haemostasis, 2012, 107, 140-149.	3.4	30
194	Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway. Thrombosis and Haemostasis, 2014, 112, 1002-1013.	3.4	30
195	ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Research, 2020, 48, 2676-2693.	14.5	30
196	Quantification of <i>PKC</i> family genes in sporadic breast cancer by qRTâ€PCR: Evidence that <i>PKC</i> ι/λ overexpression is an independent prognostic factor. International Journal of Cancer, 2012, 131, 2852-2862.	5.1	29
197	Reduction of MicroRNA 122 Expression in <i>IFNL3</i> CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C. Journal of Virology, 2014, 88, 6394-6402.	3.4	29
198	Correlation between messenger RNA expression and protein expression of immune checkpoint–associated molecules in bladder urothelial carcinoma: A retrospective study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 257-263.	1.6	29

#	Article	IF	Citations
199	MT1-MMP targeting to endolysosomes is mediated by flotillin upregulation. Journal of Cell Science, 2018, 131, .	2.0	29
200	HPV circulating tumor DNA to monitor the efficacy of antiâ€PDâ€1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. International Journal of Cancer, 2017, 141, 1667-1670.	5.1	29
201	Role of matrix metalloproteinases, proinflammatory cytokines, and oxidative stress–derived molecules in hepatitis C virus–associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis and Rheumatism, 2007, 56, 1315-1324.	6.7	28
202	Identification of New Candidate Therapeutic Target Genes in Triple-Negative Breast Cancer. Genes and Cancer, 2012, 3, 63-70.	1.9	28
203	Variations in the mRNA expression of <i>poly(ADPâ€ribose) polymerases</i> , <i>poly(ADPâ€ribose) glycohydrolase</i> and <i>ADPâ€ribosylhydrolase 3</i> in breast tumors and impact on clinical outcome. International Journal of Cancer, 2013, 133, 2791-2800.	5.1	28
204	Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. Clinical Cancer Research, 2017, 23, 2116-2126.	7.0	28
205	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discovery, 2022, 12, 1435-1448.	9.4	28
206	Loss of heterozygosity on 7q31 occurs early during breast tumorigenesis. Genes Chromosomes and Cancer, 1995, 12, 304-306.	2.8	27
207	Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions. Cell Adhesion and Migration, 2011, 5, 332-343.	2.7	27
208	Identification of PHRF1 as a Tumor Suppressor that Promotes the TGF-β Cytostatic Program through Selective Release of TGIF-Driven PML Inactivation. Cell Reports, 2013, 4, 530-541.	6.4	27
209	Involvement of Aryl hydrocarbon receptor in myelination and in human nerve sheath tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1319-E1328.	7.1	27
210	<i>MED12</i> mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways. Oncotarget, 2016, 7, 84428-84438.	1.8	27
211	Oligonucleotide microarray analysis of estrogen receptor $\hat{l}\pm$ -positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. Journal of Molecular Endocrinology, 2007, 39, 305-318.	2.5	26
212	Gene Expression Study of Aurora-A Reveals Implication During Bladder Carcinogenesis and Increasing Values in Invasive Urothelial Cancer. Urology, 2008, 72, 873-877.	1.0	26
213	Interleukin 8 is differently expressed and modulated by PARâ€1 activation in early and late endothelial progenitor cells. Journal of Cellular and Molecular Medicine, 2009, 13, 2534-2546.	3.6	26
214	VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX. BMC Biology, 2018, 16, 109.	3.8	26
215	Evidence of chromosome regions and gene involvement in inflammatory breast cancer. International Journal of Cancer, 2002, 102, 618-622.	5.1	25
216	Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1-3 by quantitative RT-PCR. Drug Metabolism and Disposition, 2005, 33, 1803-10.	3.3	25

#	Article	IF	Citations
217	Significant gene expression differences in histologically "Normal―liver biopsies: Implications for control tissue. Hepatology, 2008, 48, 953-962.	7.3	25
218	Arpin downregulation in breast cancer is associated with poor prognosis. British Journal of Cancer, 2016, 114, 545-553.	6.4	25
219	Neuronal Cholesterol Accumulation Induced by Cyp46a1 Down-Regulation in Mouse Hippocampus Disrupts Brain Lipid Homeostasis. Frontiers in Molecular Neuroscience, 2017, 10, 211.	2.9	25
220	Loss of the deglutamylase CCP5 perturbs multiple steps of spermatogenesis and leads to male infertility. Journal of Cell Science, 2019, 132, .	2.0	25
221	Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family. Human Mutation, 2003, 21, 654-654.	2.5	24
222	Quantitative RT-PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and human. Molecular Brain Research, 2003, 114, 55-64.	2.3	24
223	An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition. BMC Medical Genetics, 2011, 12, 121.	2.1	24
224	Malignant Germ Cell–Like Tumors, Expressing Ki-1 Antigen (CD30), Are Revealed during in Vivo Differentiation of Partially Reprogrammed Human-Induced Pluripotent Stem Cells. American Journal of Pathology, 2012, 180, 2084-2096.	3.8	24
225	Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients. Cell Cycle, 2015, 14, 3066-3078.	2.6	24
226	Thrombin receptor PAR-1 activation on endothelial progenitor cells enhances chemotaxis-associated genes expression and leukocyte recruitment by a COX-2-dependent mechanism. Angiogenesis, 2015, 18, 347-359.	7.2	24
227	Novel Mouse Model of Monocular Amaurosis Fugax. Stroke, 2007, 38, 3237-3244.	2.0	23
228	Protein kinase D1 regulates <scp>ER</scp> αâ€positive breast cancer cell growth response to 17βâ€estradiol and contributes to poor prognosis in patients. Journal of Cellular and Molecular Medicine, 2014, 18, 2536-2552.	3.6	23
229	Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. Oncotarget, 2018, 9, 464-476.	1.8	23
230	Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma. Cancer Biology and Medicine, 2020, 17, 208-217.	3.0	23
231	The CGA gene as new predictor of the response to endocrine therapy in $ER\hat{l}_{\pm}$ -positive postmenopausal breast cancer patients. Oncogene, 2001, 20, 6955-6959.	5.9	22
232	The trimeric coiledâ€coil <scp>HSBP</scp> 1 protein promotes <scp>WASH</scp> complex assembly at centrosomes. EMBO Journal, 2018, 37, .	7.8	22
233	Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). JCO Precision Oncology, 2021, 5, 215-226.	3.0	22
234	hTERT expression in sporadic renal cell carcinomas. Journal of Pathology, 2001, 195, 209-217.	4.5	21

#	Article	IF	CITATIONS
235	Association Analysis Indicates That a Variant GATA-Binding Site in the <i>PIK3CB</i> Promoter Is a Cis-Acting Expression Quantitative Trait Locus for This Gene and Attenuates Insulin Resistance in Obese Children. Diabetes, 2008, 57, 494-502.	0.6	21
236	$\hat{l}\pm 6$ -Integrin Is Required for the Adhesion and Vasculogenic Potential of Hemangioma Stem Cells. Stem Cells, 2014, 32, 684-693.	3.2	21
237	Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings. BMC Cancer, 2014, 14, 178.	2.6	21
238	High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL–ARF Bidirectional Promoter. Non-coding RNA, 2019, 5, 44.	2.6	21
239	Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1405-1436.	4.5	21
240	The mitochondrially-localized nucleoside diphosphate kinase D (NME4) is a novel metastasis suppressor. BMC Biology, 2021, 19, 228.	3.8	21
241	Gene Expression Profiling of ErbB Receptors and Ligands in Human Meningiomas. Cancer Investigation, 2009, 27, 691-698.	1.3	20
242	In utero and lactational exposure to vinclozolin and genistein induces genomic changes in the rat mammary gland. Journal of Endocrinology, 2013, 216, 245-263.	2.6	20
243	CAG repeat size in Huntingtin alleles is associated with cancer prognosis. European Journal of Human Genetics, 2016, 24, 1310-1315.	2.8	19
244	Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness. Acta Neuropathologica, 2018, 135, 267-283.	7.7	19
245	Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas. Cancers, 2019, 11, 1846.	3.7	19
246	Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance. Oncogene, 2021, 40, 4019-4032.	5.9	19
247	Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2001, 114, 281-289.	2.5	18
248	Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: A candidate biomarker to predict EGFR inhibitor effectiveness. International Journal of Cancer, 2012, 131, 1009-1010.	5.1	18
249	The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the \hat{l}^2 -Catenin Coactivator BCL9-2 in Breast Cancer Cells. Molecular Cancer Research, 2015, 13, 902-912.	3.4	18
250	Alternative splicingâ€regulated protein of hepatitis B virus hacks the TNFâ€Î±â€stimulated signaling pathways and limits the extent of liver inflammation. FASEB Journal, 2015, 29, 1879-1889.	0.5	18
251	Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer. Oncology Letters, 2019, 18, 674-686.	1.8	18
252	High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of <i>GPR126</i> in Bladder Cancer. Molecular Cancer Research, 2019, 17, 469-475.	3.4	18

#	Article	IF	CITATIONS
253	Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition. Oncotarget, 2018, 9, 29587-29600.	1.8	18
254	Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers. Oncogene, 1998, 16, 677-679.	5.9	17
255	CGA Gene (Coding for the α Subunit of Glycoprotein Hormones) Overexpression in ERα-Positive Prostate Tumors. European Urology, 2002, 41, 335-341.	1.9	17
256	p63 Gene Expression Study and Early Bladder Carcinogenesis. Urology, 2007, 70, 459-462.	1.0	17
257	16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development. Molecular Cancer Therapeutics, 2008, 7, 2817-2827.	4.1	17
258	Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes. Cancer Microenvironment, 2016, 9, 107-118.	3.1	17
259	Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts. Journal of Proteome Research, 2017, 16, 1868-1879.	3.7	17
260	Differential Expression of <i> CCN1 </i> / <i> CYR61 </i> , <i> CCN3/NOV </i> , <i> CCN4/WISP1 </i> , and <i> CCN5/WISP2 </i> in Neurofibromatosis Type 1 Tumorigenesis. Journal of Neuropathology and Experimental Neurology, 2010, 69, 60-69.	1.7	16
261	Genome-based and transcriptome-based molecular classification of breast cancer. Current Opinion in Oncology, 2011, 23, 93-99.	2.4	16
262	Human TIP49b/RUVBL2 gene: genomic structure, expression pattern, physical link to the human CGB/LHB gene cluster on chromosome 19q13.3. Annales De Génétique, 2000, 43, 69-74.	0.4	15
263	Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. British Journal of Cancer, 2017, 117, 1819-1827.	6.4	15
264	mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. Oncolmmunology, 2017, 6, e1358330.	4.6	15
265	MMP2 as an independent prognostic stratifier in oral cavity cancers. Oncolmmunology, 2020, 9, 1754094.	4.6	15
266	Molecular analysis of the FHIT gene in human prostate cancer. Oncogene, 1998, 16, 1863-1868.	5.9	14
267	MOLECULAR PROFILING OF BENIGN PROSTATIC HYPERPLASIA USING A LARGE SCALE REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION APPROACH. Journal of Urology, 2004, 172, 1382-1385.	0.4	14
268	Identification of the first intragenic deletion of the PITX2 gene causing an Axenfeld-Rieger Syndrome: case report. BMC Medical Genetics, 2006, 7, 82.	2.1	14
269	Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential. Angiogenesis, 2014, 17, 603-616.	7.2	14
270	Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2. Molecular Cancer Therapeutics, 2017, 16, 2292-2303.	4.1	14

#	Article	IF	Citations
271	Distinct expression profiles and functions of Kindlins in breast cancer. Journal of Experimental and Clinical Cancer Research, 2018, 37, 281.	8.6	14
272	P-cadherin-induced decorin secretion is required for collagen fiber alignment and directional collective cell migration. Journal of Cell Science, 2019, 132, .	2.0	14
273	PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer. Oncotarget, 2018, 9, 23208-23219.	1.8	14
274	Infrequent mutations of the MET gene in sporadic breast tumours. , 1999, 82, 908-910.		13
275	A missense variant within BRCA1 exon 23 causing exon skipping. Cancer Genetics and Cytogenetics, 2010, 202, 144-146.	1.0	13
276	Precision medicine: lessons learned from the SHIVA trial – Authors' reply. Lancet Oncology, The, 2015, 16, e581-e582.	10.7	13
277	Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences. Cancer Medicine, 2018, 7, 3213-3225.	2.8	13
278	Interaction between IGF2â€PI3K axis and cancerâ€nssociatedâ€fibroblasts promotes anal squamous carcinogenesis. International Journal of Cancer, 2019, 145, 1852-1859.	5.1	13
279	Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer. Cancers, 2020, 12, 2882.	3.7	13
280	Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. Genome Medicine, 2021, 13, 44.	8.2	13
281	Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas. Oncotarget, 2016, 7, 47418-47430.	1.8	13
282	Combination of COX-2 expression and <i>PIK3CA</i> mutation as prognostic and predictive markers for celecoxib treatment in breast cancer. Oncotarget, 2016, 7, 85124-85141.	1.8	13
283	MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics. British Journal of Cancer, 2015, 113, 773-785.	6.4	12
284	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. American Journal of Pathology, 2018, 188, 2378-2391.	3.8	12
285	Human Aortic Valve Interstitial Cells Display Proangiogenic Properties During Calcific Aortic Valve Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 41, 415-429.	2.4	12
286	Involvement of the FOXO6 transcriptional factor in breast carcinogenesis. Oncotarget, 2018, 9, 7464-7475.	1.8	12
287	High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial. Breast Cancer Research and Treatment, 2015, 153, 383-389.	2.5	11
288	PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101553.	1.5	11

#	Article	IF	CITATIONS
289	BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	11
290	SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog. Human Pathology, 2011, 42, 434-443.	2.0	10
291	Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts. PLoS ONE, 2014, 9, e104227.	2.5	10
292	Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts., 2016, 57, 4916.		10
293	Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4449-4460.	3.6	10
294	PLEKHS1: A new molecular marker predicting risk of progression of non‑muscle‑invasive bladder cancer. Oncology Letters, 2019, 18, 3471-3480.	1.8	10
295	Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. Scientific Reports, 2020, 10, 16641.	3.3	10
296	Fineâ€needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of nextâ€generation sequencing in cancer patients included in the SHIVAO2 trial. Molecular Oncology, 2021, 15, 104-115.	4.6	10
297	Definition of Biologically Distinct Groups of Conjunctival Melanomas According to Etiological Factors and Implications for Precision Medicine. Cancers, 2021, 13, 3836.	3.7	10
298	Abstract CTO41: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial., $2016,$		10
299	Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft. Cancers, 2022, 14, 1486.	3.7	10
300	Isolation of mineralizing Nestin+ Nkx6.1+ vascular muscular cells from the adult human spinal cord. BMC Neuroscience, 2011, 12, 99.	1.9	9
301	Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Investigational New Drugs, 2021, 39, 1641-1648.	2.6	9
302	COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients. Anticancer Research, 2018, 38, 1485-1490.	1.1	9
303	IF135, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C. PLoS ONE, 2015, 10, e0121395.	2.5	8
304	Brief communications oncogene amplification per se: An independent prognostic factor in human breast cancer. Molecular Carcinogenesis, 1994, 11, 189-191.	2.7	7
305	A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas. PLoS ONE, 2013, 8, e66574.	2.5	7
306	Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant. Breast Cancer Research, 2021, 23, 57.	5.0	7

#	Article	IF	CITATIONS
307	HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. Journal of Hematology and Oncology, 2021, 14, 143.	17.0	7
308	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. Journal of Clinical Pathology, 2023, 76, 126-132.	2.0	7
309	Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma. Cancers, 2022, 14, 1606.	3.7	7
310	Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinoma. Molecular Oncology, 2022, 16, 3001-3016.	4.6	7
311	Is Quantitative Real-Time RT-PCR an Adjunct to Immunohistochemistry for the Evaluation of ErbB2 Status in Transitional Carcinoma of the Bladder?. European Urology, 2006, 49, 1035-1043.	1.9	6
312	Biopathological Significance of PIWI–piRNA Pathway Deregulation in Invasive Breast Carcinomas. Cancers, 2020, 12, 2833.	3.7	6
313	Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials. Translational Oncology, 2021, 14, 101133.	3.7	6
314	Upregulated flotillins and sphingosine kinase 2 derail AXL vesicular traffic to promote epithelial-mesenchymal transition. Journal of Cell Science, 2022, 135, .	2.0	6
315	Tubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon. EMBO Journal, 2014, 33, 2735-2735.	7.8	5
316	EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma. Scientific Reports, 2020, 10, 7998.	3.3	5
317	The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis. Scientific Reports, 2020, 10, 6920.	3.3	5
318	$5\hat{a}$ €2 Region Large Genomic Rearrangements in the BRCA1 Gene in French Families: Identification of a Tandem Triplication and Nine Distinct Deletions with Five Recurrent Breakpoints. Cancers, 2021, 13, 3171.	3.7	5
319	Novel approach to quantitative polymerase chain reaction using realâ€time detection: Application to the detection of gene amplification in breast cancer. International Journal of Cancer, 1998, 78, 661-666.	5.1	5
320	Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC) Journal of Clinical Oncology, 2015, 33, 516-516.	1.6	5
321	Rare overexpression of anaplastic lymphoma kinase gene in inflammatory and non-inflammatory breast cancer. European Journal of Cancer, 2013, 49, 2774-2776.	2.8	4
322	Midkine Lacking Its Last 40 Amino Acids Acts on Endothelial and Neuroblastoma Tumor Cells and Inhibits Tumor Development. Molecular Cancer Therapeutics, 2015, 14, 213-224.	4.1	4
323	The SHIVA01 trial: what have we learned?. Pharmacogenomics, 2017, 18, 831-834.	1.3	4
324	High <i>in vitro</i> and <i>in vivo</i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC. Oncotarget, 2021, 12, 859-872.	1.8	4

#	Article	IF	CITATIONS
325	Abstract 1687: Vandetanib as a potential new treatment for ER negative breast cancers. Cancer Research, 2015, 75, 1687-1687.	0.9	4
326	Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIRO2-Lung/IFCT 1301 Trial. Clinical Cancer Research, 2022, 28, 4018-4026.	7.0	4
327	Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer. Breast Cancer Research and Treatment, 2012, 134, 443-448.	2.5	3
328	Revisited analysis of a SHIVA 01 trial cohort using functional mutational analyses successfully predicted treatment outcome. Molecular Oncology, 2018, 12, 594-601.	4.6	3
329	Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas. Analytical Cellular Pathology, 2020, 2020, 1-10.	1.4	3
330	First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. Anticancer Research, 2018, 38, 2909-2914.	1.1	3
331	Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus–Associated Gastric Adenocarcinoma With ERBB2 Amplification. JCO Precision Oncology, 2021, 5, 370-377.	3.0	2
332	Value of the loss of heterozygosity to BRCA1 variant classification. Npj Breast Cancer, 2022, 8, 9.	5.2	2
333	HEDGEHOG PATHWAY INVOLVEMENT IN BLADDER CARCINOGENESIS: A STUDY OF 71 PATIENTS. Journal of Urology, 2008, 179, 318-319.	0.4	1
334	Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Molecular Carcinogenesis, 2000, 29, 151-158.	2.7	1
335	Abstract B166: Effects of PTXâ€008, a nonâ€peptidic topomimetic targeting galectinâ€1 in human epithelial cancer cells. , 2009, , .		1
336	PI3KCA mutation as an independent pronostic factor in anal squamous cell carcinoma treated by abdomino-perineal resection: Evidence from a retrospective cohort of 148 patients Journal of Clinical Oncology, 2016, 34, e15060-e15060.	1.6	1
337	Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSé Program Journal of Clinical Oncology, 2016, 34, TPS11620-TPS11620.	1.6	1
338	Abstract 1524: Mutations and gene copy number variations landscape of metastases of various cancer types from patients enrolled in the SHIVA trial. , 2016 , , .		1
339	Differential Expression of Genes Involved in Metabolism and Immune Response in Diffuse and Intestinal Gastric Cancers, a Pilot Ptudy. Biomedicines, 2022, 10, 240.	3.2	1
340	Design and statistical principles of the SHIVA trial. Chinese Clinical Oncology, 2015, 4, 32.	1.2	1
341	Expression profiling in liver cirrhosis and hepatocellular carcinoma (HCC) using a large scale real time RT-PCR approach. Journal of Hepatology, 2002, 36, 73.	3.7	0
342	MRNA EXPRESSION LEVELS AND PROGNOSTIC VALUE OF 40 ANGIOGENIC GENES IN A LARGE SERIES OF 157 BLADDER TUMORS. Journal of Urology, 2008, 179, 266-266.	0.4	0

#	Article	IF	CITATIONS
343	Correction: Genome-Wide DNA Methylation Profiling of CpG Islands in Breast Cancer Identifies Novel Genes Associated with Tumorigenicity. Cancer Research, 2012, 72, 3115-3115.	0.9	0
344	Interleukin-8 Receptors CXCR1 and CXCR2 Are Not Expressed by Endothelial Colony-forming Cells. Stem Cell Reviews and Reports, 2021, 17, 628-638.	3.8	0
345	773: Loss of Expression of Candidate Tumor Suppressor Gene ATIP/MTUS1 in Human Transitional Cell Carcinoma of the Bladder. Journal of Urology, 2007, 177, 259-259.	0.4	0
346	Abstract B151: Epithelialâ€toâ€mesenchymal transition (EMT) in resistance to the antiproliferative effects of elisidepsin (Irvalecâ"¢), a novel marineâ€derived depsipeptide, in colon cancer cells. , 2009, , .		0
347	Abstract C100: Evaluation of pyriplatin, a monofunctional cationic platinum(II) compound, in human cancer cells., 2009,,.		0
348	Abstract 178:RASSF10is frequently methylated in epithelial cancers. , 2010, , .		0
349	Abstract 165: MIRA (methylated CpG island recovery assay) assay identifies frequently methylated genes in breast cancer. , 2010, , .		0
350	Abstract 3567: Interaction of pralatrexate with the EGFR/MAPK pathway leads to synergistic activity with EGFR inhibitors. , 2011 , , .		0
351	Abstract 4264: CXCL12-CXCR4 axis in sunitinib-sensitive and -resistant hepatocarcinoma cells. , 2011, , .		0
352	Abstract 4531: Molecular determinants of sensitivity to pralatrexate in a panel of human cancer cell lines., 2011,,.		0
353	Abstract 685: PTX-008 antiproliferative effects in cancer cells are mediated though galectin-1 inhibition and MAPK-dependent G2/M cell cycle arrest. , 2011 , , .		0
354	Abstract B67: Increased CXCR4 expression and its nuclear localization are associated with invasion in sorafenib and sunitinib-tolerant hepatocarcinoma models. Clinical Cancer Research, 2012, 18, B67-B67.	7.0	0
355	Abstract 85: Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments , 2013, , .		0
356	Abstract LB-34: Similar PI3K and RTK-Ras status in patient derived colorectal cancer-xenografts and patients, 2013 , , .		0
357	Abstract LB-171: Randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Preliminary results of the feasibility of the SHIVA trial , 2013, , .		0
358	Abstract A9: Establishment and characterization of residual breast cancer patient-derived xenografts resistant to neo-adjuvant therapy , 2013 , , .		0
359	Abstract C174: Establishment of luminal breast cancer patient-derived xenografts with acquired resistance to both hormonotherapy and everolimus, 2013,,.		0
360	Predictor: Randomized phase II study of preoperative afatinib in untreated nonmetastatic head and neck squamous cell carcinoma patients (HNSCC) aiming at identifying predictive and pharmacodynamic biomarkers of efficacy Journal of Clinical Oncology, 2014, 32, TPS6105-TPS6105.	1.6	0

#	Article	IF	CITATIONS
361	Abstract LB-30: Membrane-anchored MT1-MMP downstream of p63 is essential for the transition of in situ to invasive breast carcinoma. , 2014 , , .		0
362	Abstract 4499: Activation of PI3-kinase pathway and tumor response to everolimus in patient-derived xenografts of triple-negative breast cancer. , 2014 , , .		0
363	Abstract 1732: Biomarker-driven inhibition of MET and EGFR pathways in hepatocellular and cholangiocarcinoma models with increased efficacy in a sorafenib-tolerant model., $2014, \ldots$		0
364	Abstract P2-05-06: Identification of specific gene signatures and alternative splice variants using exon array in Inflammatory breast Cancer. , 2015 , , .		0
365	Assessment of functional impact of germline BRCA1/2 variants located in noncoding regions in families with breast-ovarian cancer predisposition Journal of Clinical Oncology, 2015, 33, 1542-1542.	1.6	0
366	Abstract 2400: Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for targeted sequencing in a prospective randomized trial for personalized treatment in all tumor type: The SHIVA study., 2015,,.		0
367	mRNA expression levels and prognostic value of PD1/PDL1 and CTLA4 pathways genes in a large series of 155 bladder tumors Journal of Clinical Oncology, 2016, 34, 4523-4523.	1.6	0
368	Monitoring anti-PD-1 therapy efficacy by circulating tumor DNA: a prospective cohort Journal of Clinical Oncology, 2016, 34, 11535-11535.	1.6	0
369	Kindlinâ€1 modulates the EGFR pathway and predicts sensitivity to EGFR inhibitors across cancer types. Clinical and Translational Medicine, 2022, 12, e813.	4.0	0